Dr. John Cush RheumNow
3 years 4 months ago
CDC defines Health equity as a state where everyone has a fair & just opportunity to attain their highest level of health; requires efforts to: address injustices; overcome economic;social obstacles to health & eliminate preventable health disparities https://t.co/fYviqSBIse https://t.co/XuRZ4xJdXH
Dr. John Cush RheumNow
3 years 4 months ago
Renal Function Safe With Pegloticase-MTX Combo for Gout
For patients with uncontrolled gout, estimated glomerular filtration rate (eGFR) remained stable with combination pegloticase (Krystexxa) and methotrexate treatment, researchers reported.
https://t.co/cInxAUrQiR https://t.co/MoBKUMKfjP
Dr. John Cush RheumNow
3 years 4 months ago
Women Rheumatologists Leading in the Private Sector
There are many opportunities outside of academic medicine to flex your leadership muscle.
https://t.co/Ifusp8Crvf https://t.co/JMDjhzffOP
Collaboration has proven to be an essential ingredient for progress and innovation in rheumatology. Effective collaboration requires generosity with your time and resources. Here are some things that I’ve learned over the years about successful collaborations in rheumatology.
Dr. John Cush RheumNow
3 years 4 months ago
JAMA Dermatology Patient Education page - Sarcoidosis of the Skin https://t.co/aPbTjl3pXv https://t.co/wCbjlUeFkj
A systematic review of published literature on psoriatic arthritis (PsA), clinical features, disease activity, and patient-reported outcomes (PROs) shows generally higher levels of disease activity in women, compared to men with PsA.
A metanalysis of published reports on adults with PsA, clinical variables and outcomes identified 31 publications of 27 unique studies.
Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028.
The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey federal court's ruling that Amgen patents covering the drug were valid and that the proposed generics would infringe them.
Dr. John Cush RheumNow
3 years 4 months ago
Join us as we conclude our Women in Rheumatology campaign by focusing on what's next. Our panelists will recap the challenges addressed this month and discuss a strategy to continue supporting women in rheumatology.
https://t.co/ofr1tt90TO
@uptoTate @KDAO2011 @gwenesta_melton https://t.co/YNr6gnS5Sf
Dr. John Cush RheumNow
3 years 4 months ago
Dr. Megan E.B. Clowse discusses the differences in pregnancy planning for men and women with rheumatic disesase.
https://t.co/KLyrGbYzJc https://t.co/E2Ep6BqvBN
In this session, our panelists addressed the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?".
For someone who grew up in a family of engineers, where logic and definitive answers were absolute, I live comfortably in the gray zone of uncertainty.
Dr. John Cush RheumNow
3 years 4 months ago
Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis
Lancet Rheumatology has published a retrospective analysis showing patients receiving ICI for cancer have the same outcomes even when they have pre-existing RA.
https://t.co/Tjj827nPTT https://t.co/nBBgI9wpjR
Dr. John Cush RheumNow
3 years 4 months ago
Brigham review (2018-2022) of 47 CPPD pts: M=F, mean age 72 yrs
68% w/ acute CPP arthritis
40% w/ CPP inflammatory arthritis
62% w/ OA with CPPD.
Compared to Gout, CPPD Significant unmet Rx need & lower RAPID3 (8.1 vs 12.1) https://t.co/nFOW4FS0fp https://t.co/3n6WTg66r8
Dr. John Cush RheumNow
3 years 4 months ago
What do we know about gender equity in academic rheumatology?
Dr. Nicola Dalbeth (@NicolaDalbeth) shares her thoughts.
https://t.co/ha4UvqEygk https://t.co/tmGhFUW09t



